New radiation method aims to cut side effects in prostate cancer treatment
NCT ID NCT05668351
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new way to deliver high-dose radiation (SABR) for low- and intermediate-risk prostate cancer. The technique, called SUPR-SABR, is designed to avoid the urethra, rectum, and pudendal artery to reduce urinary and bowel side effects. About 42 men will receive five radiation sessions over 1-2 weeks, and researchers will track their quality of life and side effects for two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Stereotactic ablative body radiotherapy (SABR) with urethra, pudendal artery, and rectum sparing
What this could lead to
If successful, this approach could reduce urinary and bowel side effects from radiation therapy for prostate cancer, making treatment more tolerable.
What could go wrong
This is a small, early-phase trial with only 42 participants and no comparison group. It is not yet known if the new technique controls cancer as well as standard SABR.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical University of South Carolina Hollings Cancer Center
Charleston, South Carolina, 29425, United States